Frida Bugge Askeland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Frida Bugge Askeland has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Fredrik Schjesvold
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
4 shared publications Anna Lysén
Oslo Myeloma Center
3 shared publicationsEinar Haukås
Stavanger Universitetssjukehus
3 shared publicationsFredrik Schjesvold
3 shared publicationsAnne-Marie Rasmussen
Oslo Myeloma Center, Oslo University Hospital
2 shared publicationsGalina Tsykunova
Haukeland University Hospital
2 shared publications
Latest Publications
- Open Access
- 9 April 2026
- Published by Springer Nature in Research Square
MRD-Negative Response After VRd induction, HD-ASCT, and VRd consolidation in Transplant-Eligible Newly Diagnosed Multiple Myeloma: Phase 2 REMNANT Study with Broad Inclusion Criteria
High-dose melphalan with autologous stem-cell transplantation (HD-ASCT) prolongs progression-free survival (PFS) in transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). However, most transplant trials exclude patients >65 years or those with poor performance status, aggressive disease, or significant comorbidities, limiting data on minimal residual disease (MRD)-negativity in these populations. REMNANT is a multicenter phase 2/3 study of TE-NDMM patients aged 18–75 years with broad eligibility criteria. This primary analysis reports MRD-negative complete response (CR) from the non-randomized phase 2 cohort. Patients received four cycles of bortezomib, lenalidomide, and dexamethasone (VRd) induction, HD-ASCT, and four cycles of VRd consolidation. MRD was tested in patients achieving ≥very good partial response (VGPR) post-consolidation. Between August 2020 and September 2024, 382 patients were enrolled (median age 63; 40% ≥65 years). MRD-negative CR was observed in 127 (33%) of 382 patients’ post-consolidation and 327 (86%) achieved ≥VGPR. The 12- and 24-month PFS were 88% and 79% (median follow-up 34.7 months), with comparable outcomes in patients <65 and ≥65 years. The most common adverse events of grade 3-4 were infections (44%) and cytopenias (21%). VRd induction, HD-ASCT, and VRd consolidation were effective and safe in a TE-NDMM cohort representative of the real-word NDMM population in Norway.
- 9 April 2026
- Published by Springer Nature in Research Square
Open AccessMRD-Negative Response After VRd induction, HD-ASCT, and VRd consolidation in Transplant-Eligible Newly Diagnosed Multiple Myeloma: Phase 2 REMNANT Study with Broad Inclusion Criteria
High-dose melphalan with autologous stem-cell transplantation (HD-ASCT) prolongs progression-free survival (PFS) in transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). However, most transplant trials exclude patients >65 years or those with poor performance status, aggressive disease, or significant comorbidities, limiting data on minimal residual disease (MRD)-negativity in these populations. REMNANT is a multicenter phase 2/3 study of TE-NDMM patients aged 18–75 years with broad eligibility criteria. This primary analysis reports MRD-negative complete response (CR) from the non-randomized phase 2 cohort. Patients received four cycles of bortezomib, lenalidomide, and dexamethasone (VRd) induction, HD-ASCT, and four cycles of VRd consolidation. MRD was tested in patients achieving ≥very good partial response (VGPR) post-consolidation. Between August 2020 and September 2024, 382 patients were enrolled (median age 63; 40% ≥65 years). MRD-negative CR was observed in 127 (33%) of 382 patients’ post-consolidation and 327 (86%) achieved ≥VGPR. The 12- and 24-month PFS were 88% and 79% (median follow-up 34.7 months), with comparable outcomes in patients <65 and ≥65 years. The most common adverse events of grade 3-4 were infections (44%) and cytopenias (21%). VRd induction, HD-ASCT, and VRd consolidation were effective and safe in a TE-NDMM cohort representative of the real-word NDMM population in Norway.
- Open Access
- 1 April 2026
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 4, 20
Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”
Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”
- 1 April 2026
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 4, 20
Open AccessResponse to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”
Response to “Steroid-Limited Isatuximab-Based Quadruplet Therapy in Elderly, Transplant-Ineligible Multiple Myeloma: A REST Trial Commentary”
- Open Access
- 22 December 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 214
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
Renal impairment (RI) is a serious complication in multiple myeloma (MM), linked to poor survival and early mortality. Rapid renal recovery improves outcomes, yet patients with RI have been excluded from most key trials in transplant-eligible newly diagnosed (TE-ND) MM. REMNANT is an ongoing, academic, multicenter phase 2/3 study in TE-NDMM patients aged 18–75, regardless of baseline renal function. Here, we report a subanalysis of the non-randomized phase 2 component. All patients received four 21-day cycles of induction with bortezomib, lenalidomide, and dexamethasone. Lenalidomide was dosed higher than the recommended standard of care: 25 mg/day for eGFR ≥30 mL/min/1.73 m² and 15 mg/day for eGFR <30. Between August 2020 and September 2024, 382 patients were enrolled; 81 (21%) had RI, including seven (2%) on dialysis during cycle 1. Renal response was achieved in 77%, with complete renal response in 57%. Five dialysis-dependent patients became dialysis-independent. Overall response rates were similar, and adverse events were comparable between RI and non-RI groups, except for higher rates of anemia and thrombocytopenia in the RI cohort. Four RI patients (5%) experienced worsening renal function; two cases were possibly related to lenalidomide, both reversible. These findings support the safety and efficacy of increased lenalidomide-dosing during induction in TE-NDMM patients with RI, including those with severe impairment.
- 22 December 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 214
Open AccessOptimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
Renal impairment (RI) is a serious complication in multiple myeloma (MM), linked to poor survival and early mortality. Rapid renal recovery improves outcomes, yet patients with RI have been excluded from most key trials in transplant-eligible newly diagnosed (TE-ND) MM. REMNANT is an ongoing, academic, multicenter phase 2/3 study in TE-NDMM patients aged 18–75, regardless of baseline renal function. Here, we report a subanalysis of the non-randomized phase 2 component. All patients received four 21-day cycles of induction with bortezomib, lenalidomide, and dexamethasone. Lenalidomide was dosed higher than the recommended standard of care: 25 mg/day for eGFR ≥30 mL/min/1.73 m² and 15 mg/day for eGFR <30. Between August 2020 and September 2024, 382 patients were enrolled; 81 (21%) had RI, including seven (2%) on dialysis during cycle 1. Renal response was achieved in 77%, with complete renal response in 57%. Five dialysis-dependent patients became dialysis-independent. Overall response rates were similar, and adverse events were comparable between RI and non-RI groups, except for higher rates of anemia and thrombocytopenia in the RI cohort. Four RI patients (5%) experienced worsening renal function; two cases were possibly related to lenalidomide, both reversible. These findings support the safety and efficacy of increased lenalidomide-dosing during induction in TE-NDMM patients with RI, including those with severe impairment.
- 3 February 2025
- Published by Elsevier in The Lancet Haematology
- Vol. 12 (2) , e120-e127
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
- 3 February 2025
- Published by Elsevier in The Lancet Haematology
- Vol. 12 (2) , e120-e127
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
- 11 October 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (3) , e127-e130
Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy
- 11 October 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (3) , e127-e130
Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy
- Open Access
The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study
The treatment approach for multiple myeloma (MM) has changed in recent years. After the approval of maintenance treatment after stem cell transplant in younger patients, the paradigm of continuous treatment is now prevailing in all clinical situations of myeloma. However, the best time to initiate relapse treatment is still unclear. With increased frequency of minimal residual disease (MRD) negativity, and the established clinical benefit of this finding, one of the large clinical questions in myeloma is how to approach MRD re-appearance. In this paper, we go through the MRD technology, existing and possible uses of MRD in the clinic, and data for early treatment before we introduce the design of the ongoing REMNANT study; a randomized study with early treatment of MRD relapse after first line treatment.
Open AccessThe Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study
The treatment approach for multiple myeloma (MM) has changed in recent years. After the approval of maintenance treatment after stem cell transplant in younger patients, the paradigm of continuous treatment is now prevailing in all clinical situations of myeloma. However, the best time to initiate relapse treatment is still unclear. With increased frequency of minimal residual disease (MRD) negativity, and the established clinical benefit of this finding, one of the large clinical questions in myeloma is how to approach MRD re-appearance. In this paper, we go through the MRD technology, existing and possible uses of MRD in the clinic, and data for early treatment before we introduce the design of the ongoing REMNANT study; a randomized study with early treatment of MRD relapse after first line treatment.